Liposomal STAT3-Degrading PROTAC Prodrugs Promote Anti-Hepatocellular Carcinoma Immunity via Chemically Reprogramming Cancer Stem Cells
Source abstract
Abstract
Cancer stem cells (CSCs) with hyperactivated signal transducer and activator of transcription 3 (STAT3) are a major driver of hepatocellular carcinoma (HCC). Herein, we report a nanointegrative proteolysis-targeting chimera (PROTAC)-based STAT3 degradation strategy that enables efficient chemical reprogramming of HCC-associated CSCs, which potently inhibits CSC growth while evoking anti-HCC immune responses. The PROTAC prodrug was synthesized by conjugating the STAT3 binding domain (inS3) with a thioketal-caged E3 ligase ligand (VL-TK) via an oligo(ethylene glycol) linker (OEG) with tuned length and flexibility and encapsulating it in cRGD-modified cationic liposomes for CSC-targeted delivery while facilitating their lysosomal escape. The PROTAC prodrugs were activated by the upregulated ROS levels in CSCs and efficiently degraded STAT3 for chemical reprogramming, which would not only impair their stemness features but also remodel the immunosuppressive TME into an immunosupportive state to boost anti-HCC immunity. This strategy provides an approach for improving HCC treatment in clinics.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Protein Degradation and Inhibitors · Multiple Myeloma Research and Treatments · Ubiquitin and proteasome pathways
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Life Science, Chongqing University, Chongqing 400044, China
Center for Tissue Engineering and Stem Cell Research, School of Basic Medicine, Guizhou Medical University, Guiyang 550025, China
School of Chemistry and Chemical Engineering, Chongqing University, Chongqing 400044, China
Funding
Chongqing Municipal Science and Technology Bureau · Chongqing Graduate Student Research Innovation Project · National Natural Science Foundation of China
References (42)
Show source-provided references
1. 10.1002/hep.3130610.1002/hep.31306 ↗
2. 10.14218/JCTH.2022.0014110.14218/JCTH.2022.00141 ↗
3. 10.1038/s43018-022-00357-210.1038/s43018-022-00357-2 ↗
4. 10.3322/caac.2160910.3322/caac.21609 ↗
5. 10.1038/s41571-021-00573-210.1038/s41571-021-00573-2 ↗
6. 10.1002/hep.2977810.1002/hep.29778 ↗
7. 10.1016/j.ccr.2013.03.02310.1016/j.ccr.2013.03.023 ↗
8. 10.1186/s12943-017-0734-410.1186/s12943-017-0734-4 ↗
9. 10.1038/ncomms1360810.1038/ncomms13608 ↗
10. 10.1186/s13045-016-0307-910.1186/s13045-016-0307-9 ↗
11. 10.1158/0008-5472.CAN-21-293410.1158/0008-5472.CAN-21-2934 ↗
12. 10.1021/acsnano.3c0463610.1021/acsnano.3c04636 ↗
13. 10.1038/s41575-021-00508-310.1038/s41575-021-00508-3 ↗
14. 10.1016/j.jconrel.2020.07.02510.1016/j.jconrel.2020.07.025 ↗
15. 10.1002/adma.20210062810.1002/adma.202100628 ↗
16. 10.1038/nrc273410.1038/nrc2734 ↗
17. 10.1002/adma.20220937910.1002/adma.202209379 ↗
18. 10.1021/acs.jmedchem.1c0062910.1021/acs.jmedchem.1c00629 ↗
19. 10.1016/j.pharmthera.2018.06.00610.1016/j.pharmthera.2018.06.006 ↗
20. 10.1016/j.cclet.2022.05.03210.1016/j.cclet.2022.05.032 ↗
21. 10.1186/s12943-021-01434-310.1186/s12943-021-01434-3 ↗
22. 10.1038/s41467-020-17997-610.1038/s41467-020-17997-6 ↗
23. 10.1038/s41594-020-0438-010.1038/s41594-020-0438-0 ↗
24. 10.1016/j.cell.2019.11.03110.1016/j.cell.2019.11.031 ↗
25. 10.1038/s41589-019-0362-y10.1038/s41589-019-0362-y ↗
26. 10.1002/anie.20150797810.1002/anie.201507978 ↗
27. 10.1016/j.ddtec.2019.01.00210.1016/j.ddtec.2019.01.002 ↗
28. 10.1016/j.drudis.2020.07.01310.1016/j.drudis.2020.07.013 ↗
29. 10.1021/jacs.3c0410910.1021/jacs.3c04109 ↗
30. 10.1002/advs.20220203910.1002/advs.202202039 ↗
31. 10.1016/j.bmcl.2008.07.11410.1016/j.bmcl.2008.07.114 ↗
32. 10.1038/nchembio.185810.1038/nchembio.1858 ↗
33. 10.1002/anie.20230804910.1002/anie.202308049 ↗
34. 10.1016/j.ccell.2019.10.00210.1016/j.ccell.2019.10.002 ↗
35. 10.1016/j.ccell.2019.10.01010.1016/j.ccell.2019.10.010 ↗
36. 10.1039/D2CS00220E10.1039/D2CS00220E ↗
37. 10.1039/D1CS00762A10.1039/D1CS00762A ↗
38. 10.1016/j.apsb.2022.11.00110.1016/j.apsb.2022.11.001 ↗
39. 10.1002/adfm.20160041710.1002/adfm.201600417 ↗
40. 10.1021/jacs.3c0515910.1021/jacs.3c05159 ↗
41. 10.1002/anie.20230682410.1002/anie.202306824 ↗
42. 10.1038/onc.2015.21510.1038/onc.2015.215 ↗